NCT06280313
- Conditions
- Unresectable Hepatocellular Carcinoma
- Locations
-
- Tongji Hospital Wuhan, Hubei, China
Clinical trial condition
Unresectable Hepatocellular Carcinoma
Explore clinical trials studying Unresectable Hepatocellular Carcinoma. Study availability and eligibility vary by location and protocol.
57 public trials
17 recruiting studies
Unresectable Hepatocellular Carcinoma trial results
NCT06911255
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +10 more
- Locations
-
- Seoul National University Hospital Seoul, South Korea
NCT06909708
- Conditions
- Unresectable Hepatocellular Carcinoma
- Locations
-
- Zhongda Hospital, Southeast University Nanjing, Jiangsu, China
NCT06788353
- Conditions
- Systemic Therapy, Transarterial Chemoembolization, Unresectable Hepatocellular Carcinoma
- Locations
-
- The First Affiiated Hospital of Sun Yat-sen University Guangzhou, Guangdong, China
NCT06593964
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
- Locations
-
- Gao-Jun Teng Nanjing, China
Recruiting
Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
NCT06360042
- Conditions
- Unresectable Hepatocellular Carcinoma
- Locations
-
- Beijing Cancer Hospital Beijing, Beijing Municipality, China
Recruiting
Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC
NCT05917431
- Conditions
- Oligometastatic Disease, Unresectable Hepatocellular Carcinoma
- Locations
-
- Peking University Cancer Hospital Beijing, Beijing Municipality, China
Not Yet Recruiting
AI-Guided First-Line Immunotherapy Selection in Unresectable Hepatocellular Carcinoma
NCT07729618
- Conditions
- Unresectable Hepatocellular Carcinoma
- Locations
-
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, Hubei, China
Not Yet Recruiting
Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma
NCT07110233
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +12 more
- Locations
-
- University of California, San Francisco San Francisco, California, United States
Not Yet Recruiting
Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma
NCT07511504
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +12 more
- Locations
-
- OHSU Knight Cancer Institute Portland, Oregon, United States